Announcement

Collapse
No announcement yet.

Implementation of a rapid influenza A/B and RSV direct molecular assay improves emergency department oseltamivir use in paediatric patients

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Implementation of a rapid influenza A/B and RSV direct molecular assay improves emergency department oseltamivir use in paediatric patients

    J Med Microbiol. 2018 Jan 10. doi: 10.1099/jmm.0.000676. [Epub ahead of print]
    Implementation of a rapid influenza A/B and RSV direct molecular assay improves emergency department oseltamivir use in paediatric patients.

    Mitchell SL1, Chang YC2,3, Feemster K2,3, C?rdenas AM4,5.
    Author information

    Abstract

    PURPOSE:

    Influenza A virus (FluA), influenza B virus (FluB) and respiratory syncytial virus (RSV) illnesses increase hospitalizations during seasonal epidemics.
    METHODOLOGY:

    To determine the utility of the Simplexa FluA/B & RSV Direct Assay (Direct Flu/RSV) and its impact on oseltamivir use, we offered this assay to emergency department (ED) patients with influenza-like illness.
    RESULTS:

    Utilization of the Direct Flu/RSV provided a turnaround time (TAT) of 2 hours. Compared to the flu season prior to implementation of the Direct Flu/RSV, clinicians were more likely to prescribe 5 days of oseltamivir therapy for Direct Flu/RSV-positive patients in comparison to those with a negative test.
    CONCLUSIONS:

    Use of Direct Flu/RSV provides results rapidly, which leads to more appropriate use of oseltamivir. The ease of use of this assay and quick TAT allows for prompt decision-making, which is essential for patient care and effective disease control during the influenza season.


    PMID: 29458688 DOI: 10.1099/jmm.0.000676
Working...
X